Abstract:Abstract Activation of toll-like receptor 4 (TLR4) has been shown to be a major influence on the inflammatory signalling pathways in intestinal mucositis (IM), as demonstrated by TLR4 knock-out mice. Pharmacological TLR4 inhibition has thus been postulated as a potential new therapeutic approach for the treatment of IM but specific TLR4 inhibitors have yet to be investigated. As such, we aimed to determine whether direct TLR4 antagonism prevents inflammation in pre-clinical experimental models of IM. The non-competitive and competitive TLR4 inhibitors, TAK-242 (10 μM) and IAXO-102 (10 μM), respectively, or vehicle were added to human T84, HT-29, and U937 cell lines and mouse colonic explants 1 h before the addition of lipopolysaccharide (LPS) ( in vitro : 100 μg/mL; ex vivo : 10 μg/mL), SN-38 ( in vitro : 1 μM or 1 nM; ex vivo : 2 μM), and/or tumour necrosis factor-alpha (TNF-α) (5 μg/mL). Supernatant was collected for human IL-8 and mouse IL-6 enzyme-linked immunosorbent assays (ELISAs), as a measure of inflammatory signalling. Cell viability was measured using XTT assays. Explant tissue was used in histopathological and RT-PCR analysis for genes of interest: TLR4, MD2, CD14, MyD88, IL-6, IL-6R, CXCL2, CXCR1, CXCR2. SN-38 increased cytostasis compared to vehicle ( P < 0.0001). However, this was not prevented by either antagonist ( P > 0.05) in any of the 3 cell lines. Quantitative histological assessment scores showed no differences between vehicle and treatment groups ( P > 0.05). There were no differences in in vitro IL-8 ( P > 0.05, in all 3 cells lines) and ex vivo IL-6 ( P > 0.05) concentrations between vehicle and treatment groups. Transcript expression of all genes was similar across vehicle and treatment groups ( P > 0.05). TLR4 antagonism using specific inhibitors TAK-242 and IAXO-102 was not effective at blocking IM in these pre-clinical models of mucositis. This work indicates that specific epithelial inhibition of TLR4 with these compounds is insufficient to manage mucositis-related inflammation. Rather, TLR4 signalling through immune cells may be a more important target to prevent IM.

Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation

Investigation of TLR4 Antagonists for Prevention of Intestinal Inflammation

Toll like receptor signaling pathway as a potential therapeutic target in colorectal cancer

Pharmacological Effects of Polyphenol Phytochemicals on the Intestinal Inflammation via Targeting TLR4/NF-κB Signaling Pathway

Toll-like receptors in inflammatory bowel disease: A review of the role of phytochemicals

Inhibition of TLR4 Signaling Impedes Tumor Growth in Colitis-Associated Colon Cancer

TLR4 regulates RORγt+ regulatory T-cell responses and susceptibility to colon inflammation through interaction with Akkermansia muciniphila

Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis

Research Progress of Intervention on Toll Like Receptor 4 Signal Transduction

Recent progress in the development of Toll-like receptor (TLR) antagonists

Toll-Like Receptor 4 Signaling Integrates Intestinal Inflammation with Tumorigenesis: Lessons from the Murine Model of Colitis-Associated Cancer

Modulation of inflammation by toll-like receptor 4/nuclear factor-kappa B in diarrhea-predominant irritable bowel syndrome

The Protective Role of TLR4 in Intestinal Epithelial Cells through the Regulation of the Gut Microbiota in DSS-Induced Colitis in Mice

Toll-like receptor 4: A potential therapeutic target for multiple human diseases

Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders

TLR4 monoclonal antibody blockade suppresses dextran-sulfate-sodium-induced colitis in mice.

Resatorvid (TAK-242) Ameliorates Ulcerative Colitis by Modulating Macrophage Polarization and T Helper Cell Balance Via TLR4/JAK2/STAT3 Signaling Pathway

The Cancer Prevention, Anti-Inflammatory and Anti-Oxidation of Bioactive Phytochemicals Targeting the TLR4 Signaling Pathway

TRP channels in inflammatory bowel disease: Potential therapeutic targets

Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD

The Role of Natural Products from Herbal Medicine in TLR4 Signaling for Colorectal Cancer Treatment